Theravance Biopharma (TBPH) Receivables - Other (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Receivables - Other data on file, last reported at $15.6 million in Q1 2026.

• Receivables - Other for Q1 2026 came in at $15.6 million, up 1.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.6 million (up 1.5% YoY), and the FY2025 annual result was $45.5 million, up 146.96% from the prior year.
• Receivables - Other declined to $15.6 million in Q1 2026 per TBPH's latest filing, from $45.5 million in the prior quarter.
• Over five years, Receivables - Other peaked at $45.5 million in Q4 2025 and troughed at $12.3 million in Q1 2023.
• A 5-year average of $17.6 million and a median of $15.8 million in 2023 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2022 and 2025: Receivables - Other sank 71.02% in 2022, then jumped 146.96% in 2025.
• A 5-year view of Receivables - Other shows it stood at $16.8 million in 2022, then gained by 4.1% to $17.5 million in 2023, then gained by 5.53% to $18.4 million in 2024, then soared by 146.96% to $45.5 million in 2025, then plunged by 65.78% to $15.6 million in 2026.
• Business Quant data shows TBPH's Receivables - Other at $15.6 million in Q1 2026, $45.5 million in Q4 2025, and $18.3 million in Q3 2025.